Octreotide as primary therapy for acromegaly

Journal of Clinical Endocrinology and Metabolism

Volumn 83, Issue 9, 1998, Pages 3034-3040

  Newman, Connie B ^a   Melmed, Shlomo ^b   George, Ajax ^c   Torigian, Drew ^d   Duhaney, Michael ^c   Snyder, Peter ^e   Young, William ^f   Klibanski, Anne ^g   Molitch, Mark E ^h   Gagel, Robert ⁱ   Sheeler, Leslie ^j   Cook, David ^k   Malarkey, William ^l   Jackson, Ivor ^m   Vance, Mary Lee ⁿ   Barkan, Ariel ^o   Frohman, Lawrence ^p   Kleinberg, David L ^a  

^a NEW YORK UNIVERSITY   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

^c NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^d HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f MAYO CLINIC   (United States)

^g MASSACHUSETTS GENERAL HOSPITAL   (United States)

^h NORTHWESTERN UNIVERSITY   (United States)

ⁱ UNIVERSITY OF TEXAS   (United States)

^j Innova Medical Services   (United States)

^k OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^l THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^m BROWN UNIVERSITY   (United States)

ⁿ UNIVERSITY OF VIRGINIA MEDICAL CENTER   (United States)

^o UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^p UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; OCTREOTIDE; PLACEBO; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE;

ACROMEGALY; ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; HYPOPHYSIS ADENOMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; SYMPTOMATOLOGY; TRANSSPHENOIDAL HYPOPHYSECTOMY; TUMOR VOLUME;

ACROMEGALY; ADENOMA; ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; DOUBLE-BLIND METHOD; FEMALE; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; KINETICS; MALE; MIDDLE AGED; OCTREOTIDE; PITUITARY NEOPLASMS; PLACEBOS;

EID: 7844232389     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.83.9.3034     Document Type: Article

References (27)

1. Ezzat S, Snyder PJ, Young WF, et al. 1992 Octreotide treatment of acromegaly: a randomized, multicenter study. Ann Intern Med. 117:711-718.
2. Newman CB, Melmed S, Snyder PJ, et al. 1995 Safety and efficacy of long term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients. J Clin Endocrinol Metab. 80:2768-2775.
3. Frohman LA. 1991 Therapeutic options in acromegaly. J Clin Endocrinol Metab. 72:1175-1181.
4. Melmed S, Ho K, Klibanski A, Reichlin S, Thorner M. 1995 Recent advances in pathogenesis, diagnosis, and management of acromegaly. J Clin Endocrinol Metab. 80:3395-3402.
5. Lamberts SWJ, Van der Lely A-J, De Herder WW, Hofland LJ. 1996 Octreotide. N Engl J Med. 334:246-253.
6. Barkan AL, Lloyd RV, Chandler WF, et al. 1988 Preoperative treatment of acromegaly with long-acting somatostatin analog SMS 201-995: shrinkage of invasive pituitary macroadenomas and improved surgical remission rate. J Clin Endocrinol Metab. 67:1040-1048.
7. Sassolas G, Harris AG, James-Deidier A, French SMS 201-995 Acromegaly Study Group. 1990 Long term effect of incremetal doses of the somatostatin analog SMS 201-995 in 58 acromegalic patients. J Clin Endocrinol Metab. 71:391-397.
8. Vance ML, Harris AG. 1991 Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide. Results of the international multicenter acromegaly study group. Arch Intern Med. 151:1573-1578.
9. Roelfsema F, Van Dulken H, Frolich M. 1985 Long-term results of transsphenoidal pituitary microsurgery in 60 acromegalic patients. Clin Endocrinol (Oxf). 23:555-565.
10. Ross DA, Wilson CB. 1998 Results of transsphenoidal microsurgery for growth hormone-secreting pituitary adenoma in a series of 214 patients. J Neurosurg. 68:854-867.
11. Davis DH, Laws ER, Ilstrup DM, et al. 1993 Results of surgical treatment for growth hormone-secreting pituitary adenomas. J Neurosurg. 79:70-75.
12. Fahlbusch R, Honegger J, Buchfelder M. 1992 Surgical management of acromegaly. Endocrinol Metab Clin N Amer. 21:669-692.
13. Sheaves R, Jenkins P, Blackburn R, et al. 1996 Outcome of transsphenoidal surgery for acromegaly using strict criteria for surgical cure. Clin Endocrinol (Oxf). 45:407-413.
14. Bates AS, Van't Hoff W, Jones JM, Clayton RN. 1995 Does treatment of acromegaly alter life expectancy? Metabolism. 44(Suppl 1):1-5.
15. Wright AD, Hill DM, Lowy C, Fraser TR. 1970 Mortality in acromegaly. Q J Med. 39:1-16.
16. Alexander L, Appleton D, Hall R, Ross WM, Wilkinson R. 1980 Epidemiology of acromegaly in the Newcastle region. Clin Endocrinol (Oxf). 12:71-79.
17. Bengtsson B-A, Eden S, Ernest I, Oden A, Sjogren B. 1998 Epedimiology and long-term survival on acromegaly. A study of 166 cases diagnosed between 1955 and 1984. Acta Med Scand. 223:327-335.
18. Stevenaert A, Harris AG, Kovacs K, Beckers A. 1992 Presurgical octreotide treatment in acromegaly. Metabolism. 41(Suppl 2):51-58.
19. Colao A, Ferone D, Capppabianca P, et al. 1997 Effect of octreotide pretreatment on surgical outcome in acromegaly. J Clin Endocrinol Metab. 82:3308-3314.
20. Stewart PM, Kane KF, Stewart SE, Lancranjan I, Sheppard MC. 1995 Deopt long-acting somatostatin analog (sandostatin-LAR) is an effective treatment for acromegaly. J Clin Endocrinol Metab. 80:3267-3272.
21. Caron P, Morange-Ramos I, Cogne M, Jaquet P. 1997 Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide. J Clin Endocrinol Metab. 82:18-22.
22. Flogstad AK, Halse J, Barke S, et. al. 1997 Sandostatin LAR in acromegalic patients: long term treatment. J Clin Endocrinol Metab. 81:23-28.
23. Fleiss J. 1981 Statistical methods for rates and proportions, 2nd Ed. New York: Oxford University Press.
24. Barkan AL, Halasz I, Dornfield KJ, et al. 1997 Pituitary irradiation is ineffective in normalizing plasma insulin-like growth factor 1 in patients with acromegaly. J Clin Endocrinol Metab. 82:3187-3191.
25. Acromegaly Therapy Consensus Development Panel. 1994 Consensus statement benefits vs. risks of medical theraphy for acromegaly. Am J Med. 97:468-473.
26. Newman CB. 1997 Acromegaly. In: Bardin CW, ed. Current theraphy in endocrinology and metabolism, 6th Ed. St. Louis; Mosby.
27. Halse J, Harris AG, Kvistborg A, et al. 1990 A randomized study of SMS 201-995 vs. bromocriptine treatment in acromegaly: clinical and biochemical effects. J Clin Endocrinol Metab. 70:1254-1261.